Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study by Nguyen, Ai-Lan et al.
Archived at the Flinders Academic Commons: 
http://dspace.flinders.edu.au/dspace/ 
‘This is the peer reviewed version of the following article: 
Nguyen, A.-L., Havrdova, E. K., Horakova, D., Izquierdo, G., 
Kalincik, T., van der Walt, A., … Jokubaitis, V. (2019). 
Incidence of pregnancy and disease-modifying therapy 
exposure trends in women with multiple sclerosis: A 
contemporary cohort study. Multiple Sclerosis and Related 
Disorders, 28, 235–243. https://doi.org/10.1016/
j.msard.2019.01.003 
which has been published in final form at 
https://doi.org/10.1016/j.msard.2019.01.003
© 2019 Elsevier BV. This manuscript version is made 
available under the CC-BY-NC-ND 4.0 license:
http://creativecommons.org/licenses/by-nc-nd/4.0/ 
 Accepted Manuscript
Incidence of pregnancy and disease-modifying therapy exposure
trends in women with multiple sclerosis: a contemporary cohort study
Ai-Lan Nguyen , Eva Kubala Havrdova , Dana Horakova ,
Guillermo Izquierdo , Tomas Kalincik , Anneke van der Walt ,
Murat Terzi , Raed Alroughani , Pierre Duquette , Marc Girard ,
Alexandre Prat , Cavit Boz , Patrizia Sola , Diana Ferraro ,
Alessandra Lugaresi , Jeannette Lechner-Scott , Michael Barnett ,
Francois Grand’Maison , Pierre Grammond , Cristina Ramo-Tello ,
Recai Turkoglu , Pamela McCombe , Eugenio Pucci ,
Maria Trojano , Franco Granella , Daniele Spitaleri ,
Vincent Van Pesch , Aysun Soysal , Celia Oreja-Guevara ,
Freek Verheul , Steve Vucic , Suzanne Hodgkinson , Mark Slee ,
Radek Ampapa , Julie Prevost , Jose Luis Sanchez Menoyo ,
Olga Skibina , Claudio Solaro , Javier Olascoaga ,
Cameron Shaw , Klaus Gregaard Madsen , Kerisha Naidoo ,
Robert Hyde , Helmut Butzkueven , Vilija Jokubaitis , On Behalf of
the MSBase Study Group
PII: S2211-0348(19)30003-3
DOI: https://doi.org/10.1016/j.msard.2019.01.003
Reference: MSARD 1109
To appear in: Multiple Sclerosis and Related Disorders
Received date: 11 September 2018
Accepted date: 1 January 2019
Please cite this article as: Ai-Lan Nguyen , Eva Kubala Havrdova , Dana Horakova ,
Guillermo Izquierdo , Tomas Kalincik , Anneke van der Walt , Murat Terzi , Raed Alroughani ,
Pierre Duquette , Marc Girard , Alexandre Prat , Cavit Boz , Patrizia Sola , Diana Ferraro ,
Alessandra Lugaresi , Jeannette Lechner-Scott , Michael Barnett , Francois Grand’Maison ,
Pierre Grammond , Cristina Ramo-Tello , Recai Turkoglu , Pamela McCombe , Eugenio Pucci ,
Maria Trojano , Franco Granella , Daniele Spitaleri , Vincent Van Pesch , Aysun Soysal ,
Celia Oreja-Guevara , Freek Verheul , Steve Vucic , Suzanne Hodgkinson , Mark Slee ,
Radek Ampapa , Julie Prevost , Jose Luis Sanchez Menoyo , Olga Skibina , Claudio Solaro ,
Javier Olascoaga , Cameron Shaw , Klaus Gregaard Madsen , Kerisha Naidoo , Robert Hyde ,
Helmut Butzkueven , Vilija Jokubaitis , On Behalf of the MSBase Study Group, Incidence
of pregnancy and disease-modifying therapy exposure trends in women with multiple scle-
rosis: a contemporary cohort study, Multiple Sclerosis and Related Disorders (2019), doi:
https://doi.org/10.1016/j.msard.2019.01.003
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service
to our customers we are providing this early version of the manuscript. The manuscript will undergo
copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please
note that during the production process errors may be discovered which could affect the content, and
all legal disclaimers that apply to the journal pertain.
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 1 
Highlights 
 We performed a retrospective study of women with relapsing-remitting MS 
 There was a low pregnancy incidence rate over the last twelve years 
 An increasing number of pregnancies were conceived on treatment over this time 
 Treatment exposure during pregnancy was short, with a median of 30 days 
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Abstract 
BACKGROUND: 
Exposure to disease-modifying therapy (DMT) during early pregnancy in women with 
relapsing-remitting MS (RRMS) may be increasing. 
OBJECTIVE:  
To retrospectively determine incidence of pregnancy, DMT exposure and pregnancy outcomes 
in women with RRMS. 
METHODS:  
We identified all women with RRMS aged 15-45 years in the MSBase Registry between 2005-
2016. Annualised pregnancy incidence rates were calculated using Poisson regression models. 
DMT exposures and pregnancy outcomes were assessed. 
RESULTS: 
Of 9,098 women meeting inclusion criteria, 1,178 (13%) women recorded 1,521 pregnancies. 
The annualised incidence rate of pregnancy was 0.042 (95% CI 0.040, 0.045). A total of 635 
(42%) reported pregnancies were conceived on DMT, increasing from 27% in 2006 to 62% in 
2016. The median duration of DMT exposure during pregnancy was 30 days (IQR: 9, 50). There 
were a higher number of induced abortions on FDA pregnancy class C/D drugs compared with 
pregnancy class B and no DMT (p=0.010); but no differences in spontaneous abortions, term or 
preterm births. 
CONCLUSIONS: 
We report low pregnancy incidence rates, with increasing number of pregnancies conceived on 
DMT over the past 12-years. The median duration of DMT exposure in pregnancy was relatively 
short at one month.  
1. Introduction 
Over the last 50 years, the prevalence and incidence of MS has risen.1 Women are three times 
more likely to develop MS than men,2 and we see an increasing female-male sex ratio in 
relapsing-remitting MS (RRMS) at higher latitudes.3 This has resulted in a growing burden of MS 
among women of childbearing age, and family planning discussions are frequent in clinical 
practice. 
 
The last two decades have seen a rise in the availability and use of disease-modifying therapies 
(DMTs) for RRMS. Unfortunately, there is limited information on the safety of DMT use during 
pregnancy, and no recognised guidelines are available; although a general recommendation is to 
discontinue DMT before conception in order to minimise risk of foetal harm. Anecdotally, 
physicians are increasingly maintaining their patients on DMT until pregnancies are confirmed. 
Large registries can provide crucial information on DMT use during pregnancy as they collect 
long-term information obtained during routine clinical practice. 
 
The MSBase Registry is a large, international observational cohort study, with long-term 
prospectively collected data. It was established in 2004 and has proven itself to be a fruitful 
platform for collaboration and evaluation of outcomes in MS.4 The aims of this study were to 1) 
retrospectively investigate the incidence of pregnancy in RRMS patients in the real-world 
setting; 2) report pregnancy incidence rates on DMT; 3) report duration of therapeutic exposure 
during pregnancy and 4) retrospectively report pregnancy outcomes.  
2. Methods 
2.1 MSBase Registry 
Data in the MSBase registry, including prospective pregnancy data, is entered in real time or 
near real time, as part of routine clinical visits. The MSBase protocol mandates minimum annual 
updates of a minimum dataset,4 together with the date of pregnancy onset or last menstrual 
period, and delivery date or abortion date reported as (DD/MM/YYYY) for all pregnancies 
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recorded. Portals for data entry were either the iMed patient record system or the MSBase 
online data entry system.4  
 
MSBase (registered with WHO International Clinical Trials Registry Platform ID 
ACTRN12605000455662), was approved by the Melbourne Health Human Research Ethics 
Committee and by the local ethics committees in all participating centres (or exemptions 
granted, according to local regulations). Written informed consent was obtained from all 
enrolled patients. 
2.2 Study population & design 
Data from the global MSBase registry dataset were extracted on 5 October 2016. Inclusion 
criteria comprised women of child-bearing age (15-45 years inclusive), prospectively enrolled 
in MSBase between 1 January 2005 and 5 October 2016, with a diagnosis of RRMS (2005 or 
2010 revised McDonald criteria).5, 6 Women who converted to secondary progressive MS 
(SPMS) were retained in the analysis. Patients with Clinically Isolated Syndrome (CIS) were 
excluded. Pregnancies prior to 2005 or prior to RRMS diagnosis were also excluded. As data 
collection in MSBase commenced in 2004, inclusion of pregnancies from 2005 meant only 
prospective data was included.  
 
Study entry date was on or after 1 January 2005, defined as the date the patient enrolled in 
MSBase, or the date when the participant turned 15. Censor date was the most recently 
recorded visit up to 5 October 2016 or when the participant turned 45. Two time epochs were 
chosen: 1 January 2005 to 31 December 2010, and 1 January 2011 to 6 October 2016, a period 
of almost 6 years each. Information collected included: demographics, clinical information, DMT 
exposure before and during pregnancy, and pregnancy outcomes. The pregnancy outcomes 
comprised: term deliveries, pre-term deliveries (<37 weeks), spontaneous abortions 
(miscarriages), induced abortions and unknown outcomes (not reported, lost to follow-up, or 
ongoing pregnancy at data extract). Expanded Disability Status Scale (EDSS) at pregnancy onset 
was taken as the closest EDSS to pregnancy start date +/- 6 months, in the absence of a 
concurrent relapse.  
 
MS therapy exposures in this cohort included injectable therapies: interferon- (IFN), 
glatiramer acetate (GA); the monoclonal antibodies: natalizumab, rituximab; the oral therapies: 
fingolimod, dimethyl fumarate (DMF); and azathioprine. According to the U.S. Food and Drug 
Administration (FDA), pregnancy categories for the above MS therapies are category B: GA; 
category C: IFN, natalizumab, rituximab, fingolimod, DMF; and category D: azathioprine.7  
2.3 Statistical analysis 
Continuous variables were assessed for normality using the Shapiro-Wilk test, and reported as 
mean ± standard deviation (SD) or median with interquartile range (IQR) and range, as 
appropriate. Categorical variables were summarised using frequencies and percentages. 
Standardised differences between groups were assessed using Cohen’s d. Annualised pregnancy 
incidence rates were calculated using Poisson regression models, with 95% confidence intervals 
(CIs) both overall and by epoch (2005-2010; 2011-2016).  Annualised pregnancy incidence 
rates were then further adjusted for age at pregnancy start, EDSS at or near pregnancy start, 
and geographic region to account for regional heterogeneity of clinical practice.  To account for 
multiple pregnancies, all models were clustered by patient with a robust estimation of variance.  
Differences in therapy use over time, and pregnancy outcomes were compared using Pearson’s 
2 or Fisher’s Exact Test. All statistical analyses were performed using Stata v14 (StataCorp, 
College Station, TX).  All analyses were 2-tailed and p<0.05 was considered significant. 
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3. Results 
3.1 Pregnancy incidence 
Across 33 countries, a total of 18,767 females aged 15-45 years inclusive with an initial 
diagnosis of RRMS from the MSBase registry were screened. 9,098 (48%) women met the study 
inclusion criteria (Figure 1). These 9,098 women recorded a total of 36,043 patient-years 
follow-up. Of this cohort, 1,178 (13%) women had 1,521 pregnancies recorded, a total of 7,445 
patient-years of observation including both pre and post pregnancy periods. We further 
identified 207 primary progressive MS (PPPMS) patients meeting the inclusion criteria, and 
recorded 8 pregnancies for 8 (3.9%) women with PPMS during this observation period 
(Supplement S3, S4). 
 
9,669 patients were excluded (Figure 1) and the baseline demographics and clinical 
characteristics of the included and excluded cohorts are shown in Table 1. Included and 
excluded cohorts were comparable on all baseline measures with the exception of follow-up 
duration (Cohen’s d =0.32). 
 
The characteristics of patients with pregnancies across the two epochs of interest are shown in 
Table 2. In the first epoch (2005-2010), the annual unadjusted incidence rate of pregnancy was 
0.040 (95% CI 0.036, 0.044). In the second epoch (2011-2016), the annual unadjusted incidence 
rate of pregnancy was 0.044 (95% CI 0.041, 0.047). Overall, the unadjusted incidence rate of 
pregnancy was 0.042 (95% CI 0.040, 0.045) between 2005 and 2016. Unadjusted pregnancy 
incidence was highest in those aged 25-30 (annualised incidence rate 0.072, 95% CI 0.065, 
0.079) and those aged 30-35 years (annualised incidence rate 0.071, 95% CI 0.065, 0.077). 
 
Adjusted analyses showed that higher EDSS scores were associated with reduced pregnancy 
incidence, with a relative incidence risk ratio of 0.96 per EDSS point (95% CI 0.93, 0.98; 
p<0.001); whereas age was not significantly associated with incidence of pregnancy when also 
accounting for disability and geographical region (p=0.65).  
 
3.2 Disease-modifying therapy (DMT) exposure  
Of the 1,521 pregnancies recorded: 42% reported DMT treatment at conception, 20% occurred 
within a year of DMT discontinuation, and 39% had no DMT exposure in the prior year (Figure 
1).  Of those pregnancies conceived on DMT, the median treatment exposure prior to conception 
was 1.46 years (IQR: 0.61, 2.82; range 0.003-13.1); while for those who stopped DMT in the 
prior year to conception, the median treatment exposure was 1.36 years (IQR: 0.70, 2.52; range 
0.003-11.4). For pregnancies that occurred when DMTs were ceased in the prior year, the 
median time to conception was 91 days (IQR: 36-179; range 1-365).  
 
Figure 2 shows the proportion of pregnancies that occurred on or off therapy during the follow-
up period. An increasing trend was seen in the number of reported pregnancies conceived on 
therapy over time, with 27% of pregnancies conceived on therapy in 2006 compared to 62% in 
2016.  Exposure to specific MS therapies during each epoch is shown in Table 3. During the first 
epoch, 145 of 478 (30%) pregnancies occurred on therapy, which increased in the second epoch 
to 490 of 1043 (47%) pregnancies (p<0.001). Of the total 635 pregnancies conceived on 
therapy, 487 (77%) were on injectables (55% IFNβ, 22% GA), 104 (16%) on natalizumab, 38 
(6%) on oral therapy (3% each for fingolimod and dimethyl fumarate), and the remaining few 
on rituximab and azathioprine. No pregnancies were conceived on teriflunomide. 
 
The annualised incidence rates of pregnancy by DMT class were similar: injectables 0.23 (95% 
CI 0.22, 0.24), oral therapies 0.26 (95% CI 0.22, 0.32) and monoclonal antibodies 0.25 (95% CI 
0.23, 0.28). The median duration of DMT exposure during pregnancy was 30 days (IQR: 9, 50; 
range 1-300) and was comparable between DMT classes: i.e. the injectable, monoclonal 
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antibody and oral therapies (Table 3). Seventy-six pregnancies had DMTs continued for the 
duration of the pregnancy (12% of pregnancies on therapy): IFN-1a i.m.=14, IFN-1b=10, 
IFN-1a i.m.=21, GA=14, natalizumab=13, fingolimod=2, rituximab=2.   
 
Of the 2 patients who conceived ‘on’ rituximab, the first patient had a single dose of rituximab 
36 days before estimated date of conception, while the second patient had rituximab 18 days 
before conception. The second patient had been on rituximab for 2 years and 11 months pre-
pregnancy, and recommenced therapy postpartum. Neither patient had rituximab dosing during 
pregnancy. 
3.3 Pregnancy outcomes 
The proportions of pregnancies with term deliveries, pre-term deliveries, spontaneous 
abortions, induced abortions or unknown outcomes are shown stratified by DMT identity in 
Table 4. Pregnancy outcomes were reported for 1,285 (84%) pregnancies.  These included 
1,134 livebirths in 1,019 women (median 1 (IQR 1,1); mean 1.11  0.49 children/woman).  We 
separated therapeutic exposure during pregnancy into three groups: no therapy, FDA 
pregnancy category B medications or FDA pregnancy category C & D medications. There were 
no differences between these three groups for term deliveries (2(2)=1.39, p=0.50), pre-term 
deliveries (2(2)=3.99, p=0.14) or spontaneous abortions (2(2)=2.02, p=0.90). More patients 
on category C & D medications had induced abortions compared to those on no therapy or 
category B medications (2(2)=9.14, p=0.01).  
 
We also compared pregnancy outcomes on individual DMTs (IFN, GA, natalizumab, DMF, 
fingolimod) to the untreated group (Table 4). Our cohort of IFN-treated patients did not have 
increased preterm births or spontaneous abortions, although a trend towards more induced 
abortions was seen (p=0.076). The natalizumab cohort had a higher proportion of induced 
abortions (p<0.001). 
4. Discussion 
In this retrospective analysis of women with pregnancies recorded in the MSBase dataset, we 
report an overall annualised incidence of pregnancy of 4.2%, with a minor increase from 4% 
between 2005-2010 to 4.4% between 2011-2016. To the author’s knowledge, no previous study 
has explored the incidence of pregnancy in women with relapse-onset MS.  
 
In our study, there was an average of 1.38 pregnancies or 1.11 livebirths per parous woman. 
This is lower than the United Nations reported global fertility rate of 2.52 children per woman 
from 2010 to 2015.8  It is also slightly lower than the rates reported in a recent French cohort, 
which found a mean number of 1.37 children per woman with MS.9 However, the French cohort 
included pregnancies that occurred before MS diagnosis, which were excluded in our study. The 
current literature does not suggest fertility is reduced in women with MS,9-11 but our results do 
add to pre-existing reports of women with MS having fewer children.9 It is unclear whether this 
reflects a biological or behavioural effect, and warrants further investigation.12  
 
The minor increase in pregnancy incidence over time accompanied by a rising proportion of 
pregnancies with DMT exposure could be a consequence of increased clinician surveillance and 
reporting, especially with the rapid expansion of DMTs in the market with largely unknown 
foetal effects. It is also likely that practices are changing, and clinicians are increasingly 
comfortable discontinuing DMTs once patients become pregnant rather than beforehand, 
especially if patients exhibit high disease activity.  
 
Overall, we found that 42% of pregnancies in our cohort were conceived on therapy, similar in 
proportion to that reported in the recent literature.13, 14 The annual proportion of pregnancies 
occurring on therapy in our cohort increased near-annually over the period of observation to a 
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maximum of 62% in 2016, in line with a Brazilian study of 142 pregnancies that reported up to 
70% had exposure to medications, predominantly injectables.15 Past observational studies have 
reported therapeutic exposure during pregnancy in the range of 7-9 weeks.13, 14 In our cohort, 
the median duration of therapy exposure during pregnancy was 30 days and similar across the 
injectable, monoclonal antibody and oral therapies, suggesting that most patients ceased 
treatment once pregnancy was confirmed.   
 
Of the patients who conceived on therapy, 12% continued treatment throughout pregnancy. The 
injectable therapies accounted for the majority (78%) of these, although 17% were on 
natalizumab, which likely represents a more active or aggressive subset of MS patients. 
Interestingly, the two patients on rituximab both had dosing about a month before conceiving. 
One patient had a single dose of rituximab 36 days before conception and a term delivery; 
whilst the other patient had been on rituximab for 3 years, was dosed 18 days before 
conception and had a pre-term delivery at 35 weeks. Limited data exists on pregnancy 
outcomes after rituximab exposure in MS. A study using the rituximab global drug safety 
database identified 153 pregnancies associated with maternal rituximab exposure and known 
pregnancy outcomes, of which only three pregnancies occurred in patients with MS. Overall, 90 
(59%) were livebirths and 22 (24%) were premature.16  
 
With regard to pregnancy outcomes, the rate of spontaneous abortions in our study (6%) is 
lower than the 8-20% reported in the general population17, 18 and in the MS literature.9 This may 
be due to under-reporting of abortions, which are not mandated in the MSBase registry. Almost 
20% of deliveries in our cohort were pre-term. This is higher than the 11% reported globally in 
2010,19 although it should be noted that there was no matched non-MS control group and a 
proportion (15%) of pregnancies in our group had no outcome reported. There are varying 
reports on the association of MS on pre-term delivery. A Taiwanese study reported a 
significantly increased risk of preterm birth in 174 MS women (13%) compared to a matched 
group without chronic disease (7%).20 Conversely, a Norwegian study showed no difference in 
preterm birth in 649 MS women (8%) compared to over 2 million controls (6%).21 This was 
further supported by a Canadian study that showed no difference in the mean gestational age 
between MS and non-MS women.22 In a systemic review of 22 papers, Finkelstjn et al (2011) 
calculated the rate of prematurity amongst pregnant women with MS to be 10%,23 although it 
should be noted that the definition of prematurity used in this paper was <38 weeks as opposed 
to <37 weeks in our study, and therefore, 10% may be an underestimate of the true value. 
 
Our study assessed differences in pregnancy outcomes and found a difference only for FDA 
pregnancy category C & D medications having a higher rate of induced abortions compared to 
those on category B medications or no therapy. Women on IFN therapy made up the majority 
of our patients on category C & D medications (70%), and further analyses of the IFN-treated 
patients did not show increased preterm births or spontaneous abortions compared to the 
untreated group, however a trend towards increased induced abortions was seen (p=0.076) 
(Table 3). Early reports suggested that IFN exposure was associated with a higher risk of foetal 
loss24 although subsequent studies do not support this.25, 26 One systemic literature review of 
fifteen studies concluded that IFN was associated with more preterm deliveries but not 
spontaneous abortions.25 There is also evidence that GA and natalizumab do not cause preterm 
birth or spontaneous abortions,1, 2, 13, 14, 25, 27 although a recent paper demonstrated that 
natalizumab exposure resulted in an increased risk of spontaneous abortions but this 
proportion (17.4%) was comparable to that expected in the general Italian population.28 Our 
study did not demonstrate an increased risk of preterm births or spontaneous abortions in 
either the GA or natalizumab groups. There are unfortunately few studies evaluating pregnancy 
outcomes on the newer DMT’s, and our study had relatively low numbers of fingolimod and 
DMF exposure during pregnancy. 
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We acknowledge the limitations to our study. As previously mentioned, pregnancy data is not 
mandated in the MSBase registry and there may be under-reporting of pregnancies, especially 
miscarriages and induced abortions which may have occurred in between clinic visits. This is 
less likely the case for livebirths as data collection is prospective and patients are frequently 
assessed every 6-12 months. There may also be a bias to report pregnancies that are exposed to 
DMTs, due to more vigilant follow-up and this may represent a selection bias of pregnancy data 
being entered in the registry. Another limitation is that there are a proportion of pregnancy 
outcomes that were unknown (15%), most notably for the fingolimod subgroup, and definitive 
conclusions should not be drawn. Our study was not specifically designed to address pregnancy 
outcomes in MS patients, and this would require stricter data capture.  
 
Further studies are necessary to explore the long-term developmental effects of DMT exposure 
in-utero. A study from the Brazilian database followed 180 pregnancies in patients with MS, 85 
of whom had exposure to DMTs for at least 2 weeks (mean 13 weeks). The 180 children had a 
mean age of almost 7 years (range 1-39), and no specific long-term adverse events or 
complications were seen in the offspring of women who had DMT exposure during pregnancy.29 
These findings are reassuring, but need to be validated in much larger population studies across 
a broader range of DMTs. 
 
In summary, we report a low annualised incidence of pregnancy in the MSBase MS cohort, 
together with an increasing proportion of pregnancies conceived on DMT over time, which 
likely reflects changing clinician and patient attitudes.  The incidence rates of pregnancy by 
therapy type were similar and the median duration of exposure was short for all the DMT 
classes.  We did not find differences in the proportion of term, pre-term births or miscarriages 
between pregnancies conceived on or off DMT, although the caveat is that a proportion of 
pregnancy outcomes were unknown. Our study’s main strength is that it utilises a large pool of 
prospectively collected data and is the largest reported observational study of DMT exposure in 
pregnancy to date, including the more recent oral therapies for which limited data are available. 
Plans are underway in the MSBase registry to improve capture of pregnancy outcomes, together 
with maternal and foetal outcomes, and this will be reported in the future. 
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Tables & Figures 
Figure 1. Flowchart for study inclusion and breakdown of pregnancies and DMT 
exposure. Patients excluded due to incomplete minimum dataset had at least one of the 
following information missing: date of birth, sex, MS diagnosis date, MS phenotype, minimum of 
one EDSS assessment. RRMS, relapsing-remitting MS; DMT, disease-modifying therapy; i.m., 
intramuscular; s.c., subcutaneous. 
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Table 1. Baseline and clinical characteristics of included cohort, pregnancies and excluded patients occurring during study period (2005-
2016). 
 
Baseline features Included cohort 
(n=9098) 
Pregnancies 
(n=1521) 
Excluded cohort~ 
(n=9669) 
Cohen’s d 
(included vs 
excluded) 
Follow-up period#, y; median (IQR; range) 3.4  
(1.5, 6.0; 0-11.6) 
6.4  
(4.1, 8.6; 0.2-11.5) 
3.1 
(0, 10.7; 0-11.6) 
-0.321 
Age*, y; median (IQR, range) 32.7  
(26.8, 38.7; 15.0-45.0) 
31.8  
(28.5, 34.8; 15.4-43.8) 
31.8 
(26.2, 37.7; 15-45) 
0.061 
Disease duration*, y; median (IQR; range) 2.1  
(0.4, 6.8; 0-38.1) 
5.1  
(2.9, 8.3; 0.1-24.7) 
2.4 
(0.6, 6.9; 0-35) 
-0.062 
EDSS*^; median (IQR; range) 2.0 
(1, 3; 0-9.5) 
1.5  
(1, 2; 0-7.5) 
2.0 
(1, 3; 0-9.5) 
-0.075 
ARR 1y prior to pregnancy+; median (IQR) NA 0  
(0,1) 
NA NA 
Pregnancies per woman; median (IQR; 
range); mean ± SD 
NA 1 (1, 2; 1-5) 
1.38  0.63 
NA NA 
EDSS, Expanded Disability Status Scale; ARR, annualised relapse rate; IQR, interquartile range; SD, standard deviation. 
~ Excluded cohort included those, whose 1st visit was prior to 2005, had no follow-up, no visit data, date incongruities, pregnancy prior to MS diagnosis 
#total follow-up period during study eligibility 
*at start of observation period for total cohort and excluded patients or start of pregnancy  
^whole cohort n=8407, pregnant cohort n=1263, excluded patients n=6704 
+n=1376 
 
 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 16 
Table 2. Baseline and clinical characteristics of pregnancies between 2005-2010 & 2011-2016. 
 
Baseline features at time of pregnancy 
 
2005-2010  2011-2016 
Number of women 410 867 
Number of pregnancies 478 1043 
Pregnancies per woman; median (IQR; 
range); mean ± SD 
1 (1,1; 1-4) 
1.17 ± 0.44 
1 (1,1; 1-5) 
1.20 ± 0.48 
Age, y; median (IQR; range) 31.3  
(28.2, 34.5; 18.6-42.5) 
31.9  
(28.6, 35.0; 15.4-43.8) 
Disease duration, y; median (IQR; range) 4.0  
(2.2, 7.3; 0.1-24.7) 
5.6  
(3.2, 8.5; 0.2-22.7) 
MS phenotype at pregnancy: 
   RRMS; n (%) 
   SPMS; n (%) 
 
461 (96.4) 
17 (3.6) 
 
1038 (99.5) 
5 (0.5) 
EDSS^; median (IQR; range) 1.5  
(1, 2; 0-6.5) 
1.5  
(1, 2; 0-7.5) 
ARR 1y prior to pregnancy+; median (IQR) 0  
(0,1) 
0  
(0,1) 
EDSS, Expanded Disability Status Scale; ARR, annualised relapse rate; IQR, interquartile range; SD, standard deviation; RRMS, relapsing-remitting MS; SPMS, 
secondary-progressive MS. 
^n=376 (2005-2010), n=896 (2011-2016) 
+n=409 (2005-2010), n=967 (2011-2016) 
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Figure 2. Proportion of pregnancies that occurred whilst on or off therapy between 2005-
2016. 
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Table 3. Pregnancies occurring on DMT (n=635) & duration of DMT use prior to and during pregnancy in each epoch: 2005-2010 & 2011-
2016 
 
DMT Pregnancies on DMT 
2005-2010 (n=145; 30% of pregnancies) 
Pregnancies on DMT 
2011-2016 (n=490; 47% of pregnancies) 
n (%) Time on therapy 
prior to 
pregnancy, y; 
median (IQR) 
Time on 
therapy during 
pregnancy, d; 
median (IQR) 
n (%) Time on therapy 
prior to 
pregnancy, y; 
median (IQR) 
Time on 
therapy during 
pregnancy, d; 
median (IQR) 
IFN-1a i.m. (n=125) 41 (28) 1.3 (0.8, 2.3) 33 (9,58) 84 (17) 2.6 (1.4, 4.2) 29 (9,40) 
IFN-1b* (n=61) 19 (13) 1.7 (0.6, 3.7) 38 (15,227) 42 (9) 1.4 (0.4, 2.3) 21 (8,42) 
IFN-1a s.c. (n=164) 39 (27) 1.9 (0.6, 2.7) 31 (16,85) 125 (26) 1.9 (0.8, 3.1) 30 (11,47) 
GA (n=137) 36 (25) 1.3 (0.8, 2.3) 52 (18,101) 101 (21) 1.4 (0.5, 2.8) 29 (5,42) 
Natalizumab (n=104)  6 (4) 0.3 (0.1, 0.8) 9 (1,68) 98 (20) 1.1 (0.4, 2.0) 24 (9,41) 
DMF (n=17) 1 (1) 0.9 30 16 (3) 0.5 (0.3, 0.9) 21 (1,31) 
Fingolimod (n=21) - - - 21 (4) 0.7 (0.5, 2.1) 25 (7,52) 
Azathioprine (n=4) 3 (2) 2.4 (1.5, 3.1) 42 (33, 112) 1 (<1) 4.2 149 
Rituximab (n=2) - - - 2 (<1)  ^ + 
IFN, interferon-; i.m., intramuscular; s.c., subcutaneous; GA, glatiramer acetate; DMF, dimethyl fumarate; IQR, interquartile range. 
* Betaferon & Extavia 
^ No median: 1 patient was on therapy for 3 years and the other patient had a single dose, pre-pregnancy 
+ In these 2 patients, conception occurred 18 and 36 days after rituximab. No rituximab was given during pregnancy 
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Table 4. DMT use during pregnancy & pregnancy outcomes 
 
Pregnancies Pregnancy outcomes 
 
Term  
(37 weeks) 
Pre-term 
(<37 weeks) 
Spontaneous 
abortion/ 
Miscarriage 
Induced 
abortion 
Unknown 
All (n=1521);  
n (%*) 
847  
(56) 
287  
(19) 
87  
(6) 
64  
(4) 
236  
(15) 
No DMT (n=886);  
n (%) 
504  
(57) 
182  
(20) 
50  
(6) 
27  
(3) 
123  
(14) 
On any DMT (635);  
n (%) 
343  
(54) 
105  
(16) 
37  
(6) 
37  
(6) 
113  
(18) 
    Pregnancies disaggregated by DMT identity 
IFN-1a i.m. (n=125);  
n (%) 
80 
(40) 
11 
(9) 
10 
(8) 
5 
(4) 
19 
(15) 
IFN-1b^ (n=61);  
n (%) 
35 
(57) 
10 
(16) 
3 
(5) 
4 
(7) 
9 
(15) 
IFN-1a s.c. (n=164);  
n (%) 
96 
(59) 
36 
(22) 
3 
(2) 
9 
(5) 
20 
(12) 
      All IFN (350);  
n (%) 
211 
(60.3) 
57 
(16.3) 
16 
(4.6) 
181 
(5.1) 
48  
(13.7) 
GA (n=137);  
n (%) 
72 
(53) 
24 
(17) 
9 
(6) 
5 
(4) 
272 
(20) 
Natalizumab (n=104); 
n (%) 
41** 
(39) 
16 
(15) 
8 
(8) 
13*** 
(13) 
26** 
(25) 
DMF (n=17);  
n (%) 
8 
(47) 
3 
(18) 
33 
(18) 
0 3 
(18) 
Fingolimod (n=21);  
n (%) 
7 
(33) 
3# 
(14) 
1 
(5) 
1 
(5) 
9## 
(43) 
Azathioprine (n=4);  
n (%) 
3 
(75) 
1 
(25) 
0 0 0 
Rituximab (n=2)+;  
n (%) 
1 
(50) 
1 
(50) 
0 0 0 
IFN, interferon-; i.m., intramuscular; s.c., subcutaneous; GA, glatiramer acetate; DMF, dimethyl 
fumarate. 
* Percentage of pregnancy outcome 
^ Betaferon & Extavia 
+ The patient with a single (pre-pregnancy) dose of rituximab had a term delivery, whilst the patient on 
rituximab for three years had a pre-term delivery at 35 weeks. 
12 ptrend=0.076 compared to no DMT exposure 
22 ptrend=0.073 compared to no DMT exposure 
**2 p<0.01 compared to no DMT exposure 
***2 p<0.001 compared to no DMT exposure 
3Fisher’s Exact ptrend=0.072 compared to no DMT exposure 
#Fisher’s Exact p<0.05 compared to no DMT exposure 
##Fisher’s Exact p<0.01 compared to no DMT exposure 
 
 
 
